While the majority of analysts are bullish on Sutro Biopharma, the decrease in the average price target could indicate a potential slowdown in the company's growth or a reassessment of its value. This could have a neutral impact on the stock price in the short term as the positive sentiment from the bullish ratings is offset by the lower price target.